SOURCE: AtheroNova Inc.

September 15, 2010 10:04 ET

AtheroNova CEO Thomas W. Gardner to Present at the Accredited Members, Inc. Fall 2010 Small Cap/Micro Cap Investment Conference

IRVINE, CA--(Marketwire - September 15, 2010) -  AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a pharmaceutical company focused on the research and development of compounds to regress atherosclerotic plaque, announced that its Chief Executive Officer Thomas W. Gardner will make a presentation on Wednesday, September 22nd at 11:00 AM Pacific during the Accredited Members, Inc. Fall 2010 Small Cap/Micro Cap Investment Conference. The conference will be held September 20th - 22nd, 2010 at the Loews Coronado Bay Resort and Spa, San Diego, CA.

Mr. Gardner's presentation will cover the Company's plans and progress to date in the research and development of compounds to regress atherosclerotic plaque. Mr. Gardner will also discuss the market potential for AtheroNova's compounds and the anticipated development timeline. The presentation will be posted on the Company's website immediately following the conference.

The conference showcases small cap and micro cap companies with promising technology. In addition to AtheroNova, the companies presenting include: FluoroPharma, Beamz Interactive, Zynex, ASHS, Blackwater Midstream, Bion Environmental, STW Resources, Echo Therapeutics, Santo Spirits, Terra Gold, Best Energy, and Valcent Products Inc.

About AtheroNova Inc. and AtheroNova Operations, Inc.

AtheroNova, through its wholly-owned subsidiary, AtheroNova Operations, is a development stage company currently researching novel patents-pending applications of certain natural compounds to regress atherosclerotic plaque deposits, a process called delipidization. The company is currently developing protocols for its second animal study at the Cedars-Sinai Division of Cardiology in conjunction with a major university to validate the findings of its initial study and prepare for human trials. The Company plans to develop multiple applications for its compounds, to be used in pharmaceutical grade products for the treatment of atherosclerosis. Prior to May 13, 2010, AtheroNova was a public "shell" company with nominal assets whose sole business was to identify, evaluate and investigate various companies to acquire or with which to merge.

Additional information about the AtheroNova / AtheroNova Operations merger, capital raise transaction and AtheroNova Operations, Inc. (formerly Z&Z Medical Holdings, Inc.), can be found in AtheroNova's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 20, 2010.

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward looking statements in this news release include statements regarding completion of AtheroNova's restructuring, commencement of the second animal trial and the development of applications for AtheroNova's compounds. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in AtheroNova's filings with the United States Securities and Exchange Commission. AtheroNova undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

  • Contact:

    Company Contact:
    Thomas Gardner
    Chief Executive Officer
    or
    Mark Selawski
    Chief Financial Officer
    (949) 476-1100

    Investor Contact:
    Leon Hamerling
    Investor Media Group
    877-725-2500